Factors influencing community acceptability of mass drug administration for the elimination of onchocerciasis in the Asante Akim South Municipal, Ghana.
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
received:
07
09
2022
accepted:
17
03
2023
revised:
12
04
2023
medline:
14
4
2023
pubmed:
1
4
2023
entrez:
31
3
2023
Statut:
epublish
Résumé
Onchocerciasis is one of the eleven neglected tropical diseases (NTDs) recently targeted by the World Health Organization (WHO) for elimination. Mass drug administration (MDA) of ivermectin has become the main intervention for reducing the burden of onchocerciasis and controlling its transmission. However, despite the considerable gains in the fight against onchocerciasis in Ghana, the infection remains endemic in some communities. This study aimed to ascertain community members' acceptability levels and factors associated with ivermectin MDA for the elimination of onchocerciasis in the Asante Akim South Municipal in the Ashanti Region of Ghana. A cross-sectional, questionnaire-based study was conducted in six communities in the Asante Akim South Municipal from 7th May to 9th July, 2021. The study population comprised all persons aged 18 years and above who had lived in the study communities for more than three months prior to the study. The main outcome variable was the acceptability of ivermectin MDA by the community members. This was measured using a composite acceptability score adapted from the Intervention Rating Profile tool. The explanatory variables were the respondents' socio-demographic characteristics, self-rated knowledge of onchocerciasis, perceived side effects of ivermectin, and self-reported level of education received on MDA activities. Out of 450 community members included in the study, 50.4% were male while 49.6% were female. The respondents' mean age was 39.57±10.64 years. The mean acceptability score for ivermectin MDA was 20.52±2.91 (range, 9-36). Acceptability of ivermectin MDA was positively associated with gender, educational status, employment status, self-rated knowledge of onchocerciasis, and level of education received on MDA; and negatively associated with perceived side effect of ivermectin. This study provides valuable information to inform policy decisions on planning and implementing MDA programs for the elimination of onchocerciasis in the study area and the country as a whole.
Identifiants
pubmed: 37000840
doi: 10.1371/journal.pntd.0011251
pii: PNTD-D-22-01164
pmc: PMC10096254
doi:
Substances chimiques
Ivermectin
70288-86-7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0011251Informations de copyright
Copyright: © 2023 Kumah et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests
Références
Trop Med Infect Dis. 2018 Sep 01;3(3):
pubmed: 30274490
ACS Infect Dis. 2018 Oct 12;4(10):1423-1431
pubmed: 30141624
Clin Infect Dis. 2020 Aug 14;71(4):933-943
pubmed: 31536624
PLoS Negl Trop Dis. 2016 Nov 3;10(11):e0005027
pubmed: 27812107
Int Health. 2016 Mar;8(2):116-23
pubmed: 26152231
Parasit Vectors. 2014 Mar 10;7:98
pubmed: 24612494
PLoS Negl Trop Dis. 2016 Oct 5;10(10):e0004954
pubmed: 27706162
J Med Internet Res. 2016 Mar 08;18(3):e60
pubmed: 26957477
BMC Infect Dis. 2019 May 17;19(1):431
pubmed: 31101085
Trop Med Infect Dis. 2019 Jun 13;4(2):
pubmed: 31200509
PLoS Negl Trop Dis. 2013 Nov 21;7(11):e2447
pubmed: 24278486
PLoS Negl Trop Dis. 2021 Sep 20;15(9):e0009596
pubmed: 34543269
Trans R Soc Trop Med Hyg. 2012 Jun;106(6):340-7
pubmed: 22513165
Acta Trop. 2018 Sep;185:357-362
pubmed: 29932933
Infect Disord Drug Targets. 2020;20(2):167-174
pubmed: 30727921
Clin Infect Dis. 2022 Sep 29;75(6):959-967
pubmed: 35088849
Res Synth Methods. 2012 Jun;3(2):80-97
pubmed: 26062083
Int J Parasitol Drugs Drug Resist. 2012 Feb 12;2:20-8
pubmed: 24533268
Trends Parasitol. 2012 Jul;28(7):280-8
pubmed: 22633470
EC Microbiol. 2019 Mar;15(3):160-167
pubmed: 30957099
AIDS Behav. 2008 Mar;12(2):272-83
pubmed: 17592763
Br J Health Psychol. 2018 Sep;23(3):519-531
pubmed: 29453791